Clinical trial · Observational
Feasibility and Safety of Using Nasal High Flow Oxygen Postoperatively to Reduce Respiratory Complications
Evaluating the Feasibility and Safety of Using Nasal High Flow Oxygen for Five Days Postoperatively to Reduce Respiratory Complications After Oesophagectomy for Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Covid-19
Summary
Brief summary (as posted)
The use of nasal high flow in patients undergoing oesophagectomy is a novel technique that has not been previously studied. Nasal high flow will be delivered postoperatively to patients undergoing oesophagectomy in a tertiary cancer referral centre. This single-centre cohort study will evaluate the safety of using nasal high flow in oesophagectomy patients. Physiological parameters, adverse events and clinical outcome will be recorded in consecutive patients undergoing oesophagogastric surgery. This study will challenge the hypothesis that the use of nasal high-flow will lower the rates of breathing complications such as pneumonia thereby reducing the demands on intensive care, shortening hospital stay and improving patient quality of life. The results will inform the design of a larger multicentre clinical trial comparing nasal high flow to conventional methods by facilitating sample size calculation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of the Esophagus | Malignant Esophageal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nasal High flow Oxygen | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Nasal High flow Oxygen
- description
- Following consent, the participant will undergo Oesophagectomy as per routine care. During surgery, prior to trial participation and as per standard of care at the site, a nasogastric tube will be placed into the gastric conduit and secured to the nose. This tube will be left on free drainage and aspirated every 4 hours to check for inadvertent insufflation.
- interventionNames
- Device: Nasal High flow Oxygen
Primary outcomes (1)
- measure
- Rate of respiratory complications within 30 days after surgery
- timeFrame
- 30 days
- description
- including pneumonia, pleural effusion, adult respiratory distress syndrome and pulmonary embolism.
Secondary outcomes (6)
- measure
- 30 day mortality
- timeFrame
- 30 days
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Over 18 years old * Undergoing Ivor-Lewis (2-stage) oesophagectomy * Successfully extubated within 4 hours after surgery Exclusion Criteria: * History of bullous emphysematous disease * Lack of capacity to consent * Significant air leak during surgery * Incurable disease found at surgery leading to no surgical resection * Failure of extubation and spontaneous breathing within 4 hours after surgery
References
Publications (0)
Data not yet available